SHCR · Sharecare, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.27M | $90.86M | - | $113.33M | $110.35M | $116.30M | - | $114.62M | $103.82M | $100.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $39.69M | $34.91M | - | $35.25M | $35.37M | $34.12M | - | $38.55M | $43.49M | $56.00M |
| Total Operating Expenses | $135.42M | $127.46M | - | $143.05M | $144.50M | $152.95M | - | $140.09M | $102.86M | $102.59M |
| D&A | - | $13.33M | - | - | - | $14.78M | - | - | - | $6.68M |
| Operating Income | ($41.15M) | ($36.60M) | - | ($29.72M) | ($34.14M) | ($36.65M) | - | ($25.48M) | ($35.64M) | ($50.59M) |
| Interest Expense | $453.0K | $217.0K | - | $513.0K | $453.0K | $430.0K | - | $548.0K | $539.0K | $492.0K |
| Income Tax | $37.0K | ($31.0K) | - | ($43.0K) | $65.0K | $31.0K | - | ($627.0K) | $269.0K | $92.0K |
| Net Income | ($42.04M) | ($35.09M) | - | ($24.45M) | ($35.14M) | ($34.66M) | - | ($27.36M) | ($29.02M) | ($38.20M) |
| EPS - Basic | ($0.12) | ($0.10) | - | ($0.07) | ($0.10) | ($0.10) | - | ($0.08) | ($0.08) | ($0.11) |
| EPS - Diluted | ($0.12) | ($0.10) | - | ($0.07) | ($0.10) | ($0.10) | - | ($0.08) | ($0.09) | ($0.14) |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.15M | $100.32M | $128.19M | $128.01M | $144.16M | $154.43M | $182.51M | $202.56M | $211.57M | $253.31M |
| Accounts Receivable | $130.52M | $124.94M | $128.17M | $125.05M | $123.86M | $116.28M | $116.88M | $99.66M | $98.72M | $95.25M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $48.10M | $45.53M | $45.39M | $26.64M | $25.72M | $23.05M | $8.84M | $12.21M | $21.20M | $27.32M |
| Current Assets | $229.81M | $240.16M | $267.81M | $268.40M | $285.66M | $292.29M | $320.63M | $319.26M | $327.90M | $365.66M |
| Total Assets | $560.20M | $578.63M | $613.63M | $629.60M | $655.39M | $668.57M | $701.00M | $710.68M | $701.06M | $739.23M |
| Current Liabilities | $113.93M | $106.78M | $116.61M | $110.61M | $112.99M | $99.55M | $101.03M | $89.94M | $76.76M | $98.17M |
| Long-term Debt | $0 | $586.0K | $519.0K | $450.0K | $364.0K | $224.0K | $0 | - | - | - |
| Total Liabilities | $122.39M | $114.86M | $125.56M | $119.80M | $126.22M | $113.34M | $120.20M | $116.29M | $90.21M | $118.22M |
| Stockholders' Equity | $379.90M | $405.89M | $430.14M | $452.13M | $470.58M | $496.16M | $521.45M | $534.98M | $551.30M | $560.79M |
| Retained Earnings | ($802.50M) | ($760.46M) | ($725.37M) | ($691.13M) | ($666.68M) | ($631.53M) | ($595.82M) | ($571.70M) | ($544.34M) | ($515.31M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($19.59M) | - | - | - | ($23.50M) | - | - | - | ($12.09M) |
| Investing Cash Flow | - | ($5.19M) | - | - | - | ($5.17M) | - | - | - | ($8.01M) |
| Financing Cash Flow | - | ($3.04M) | - | - | - | $522.0K | - | - | - | $21.78M |
| CapEx | - | $51.0K | - | - | - | $368.0K | - | - | - | $234.0K |
| Free Cash Flow | - | ($19.64M) | - | - | - | ($23.87M) | - | - | - | ($12.33M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -43.7% | -40.3% | - | -26.2% | -30.9% | -31.5% | - | -22.2% | -34.3% | -50.2% |
| EBITDA margin | - | -25.6% | - | - | - | -18.8% | - | - | - | -43.6% |
| Net margin | -44.6% | -38.6% | - | -21.6% | -31.8% | -29.8% | - | -23.9% | -28.0% | -37.9% |
| Free cash flow margin | - | -21.6% | - | - | - | -20.5% | - | - | - | -12.2% |
| FCF / Net income | - | 0.56 | - | - | - | 0.69 | - | - | - | 0.32 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 42.1% | 38.4% | - | 31.1% | 32.1% | 29.3% | - | 33.6% | 41.9% | 55.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.5% | -6.1% | - | -3.9% | -5.4% | -5.2% | - | -3.8% | -4.1% | -5.2% |
| Return on equity | -11.1% | -8.6% | - | -5.4% | -7.5% | -7.0% | - | -5.1% | -5.3% | -6.8% |
| Return on invested capital | -8.6% | -7.1% | - | -5.2% | -5.7% | -5.8% | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.02 | 2.25 | 2.30 | 2.43 | 2.53 | 2.94 | 3.17 | 3.55 | 4.27 | 3.72 |
| Quick ratio | 2.02 | 2.25 | 2.30 | 2.43 | 2.53 | 2.94 | 3.17 | 3.55 | 4.27 | 3.72 |
| Cash ratio | 0.75 | 0.94 | 1.10 | 1.16 | 1.28 | 1.55 | 1.81 | 2.25 | 2.76 | 2.58 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| Debt / Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -90.8x | -168.7x | - | -57.9x | -75.4x | -85.2x | - | -46.5x | -66.1x | -102.8x |
| Equity multiplier | 1.47 | 1.43 | 1.43 | 1.39 | 1.39 | 1.35 | 1.34 | 1.33 | 1.27 | 1.32 |
| Liabilities / Assets | 0.22 | 0.20 | 0.20 | 0.19 | 0.19 | 0.17 | 0.17 | 0.16 | 0.13 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | 0.16 | - | 0.18 | 0.17 | 0.17 | - | 0.16 | 0.15 | 0.14 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 505d | 502d | - | 403d | 410d | 365d | - | 317d | 347d | 345d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -14.6% | -21.9% | - | -1.1% | 6.3% | 15.5% | - | 42.9% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -20.5% | 0.1% | - | -16.7% | 4.2% | 27.5% | - | 13.7% | -3860.3% | -5494.5% |
| Net income growth (YoY) | -19.6% | -1.2% | - | 10.6% | -21.1% | 9.3% | - | 36.5% | -3059.5% | - |
| EPS growth (YoY) | -20.0% | 0.0% | - | 12.5% | -11.1% | 28.6% | - | 38.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 17.7% | - | - | - | -93.6% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -19.3% | -18.2% | -17.5% | -15.5% | -14.6% | -11.5% | -7.4% | -2.4% | - | 11115.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$445.25M totalEnterprise$243.94M · 54.8%
Provider$119.34M · 26.8%
Life Sciences$81.97M · 18.4%
Peer comparison
Same SIC group: Services-Health Services
Comparing Sharecare against the 5 most active filers in the same SIC group.